首页> 外文期刊>BMC Cancer >Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma
【24h】

Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma

机译:圆形RNA表达的综合性谱揭示多发性骨髓瘤中的潜在诊断和预后生物标志物

获取原文
           

摘要

BackgroundThis study aimed to explore the heterogeneity of circRNA expression pattern via microarray, and further evaluate the potential of 10 specific circRNAs as diagnostic and prognostic biomarkers in multiple myeloma (MM).MethodsIn exploration stage (stage I), circRNA expression profiles were detected by the microarray in bone marrow plasma cells from 4 MM patients and 4 healthy controls (HCs), and bioinformatic analyses were performed. In validation stage (stage II), top 10 upregulated and top 10 downregulated circRNAs identified in stage I were detected in 60 MM patients and 30 HCs for further validation; the diagnostic and prognostic values of these circRNAs in MM patients were analyzed.ResultsIn stage I, 122 upregulated and 260 downregulated circRNAs were identified in MM patients compared with HCs. GO, KEGG and pathway enrichment analyses revealed that these circRNAs were implicated in neoplastic pathways such as MAPK and VEGF signaling pathways. In stage II, circ-PTK2, circ-RNF217, circ-RERE, circ-NAGPA and circ-KCNQ5 were validated to be upregulated and circ-AFF2, circ-WWC3, circ-DNAJC5, circ-KLHL2, circ-IQGAP1 and circ-AL137655 were validated to be downregulated in MM compared with controls. Circ-PTK2 and circ-RNF217 were correlated with poor treatment response and survival, while circ-AFF2 predicted good treatment response and survival in MM patients.ConclusionsThis study provides valuable reference for profound understanding about circRNA expression patterns in MM, and validates that circ-PTK2, circ-RNF217 and circ-AFF2 might serve as potential prognostic biomarkers in MM.
机译:背景研究旨在通过微阵列探讨Circrna表达模式的异质性,并进一步评估10个特定晶体的电位作为多发性骨髓瘤(mm)的诊断和预后生物标志物.Methodsin探索阶段(阶段I),通过CircRNA表达谱检测骨髓血浆细胞中的微阵列来自4 mm患者和4例健康对照(HCS)和生物信息分析。在验证阶段(阶段II),在60毫米患者和30 HCS中检测到阶段I中鉴定的前10名上调和前10个下调CERCRNA,以进一步验证;分析了MM患者中这些CircrNA的诊断和预后值。与HCS相比,MM患者中鉴定了第I,122阶段I,122上调和260个下调CircrNA。 GO,Kegg和途径浓缩分析显示,这些CircrNA涉及肿瘤途径,例如MAPK和VEGF信号传导途径。在第II阶段,验证了CIRC-PTK2,CIRC-RNF217,CIRC-RERE,CIRC-KCNQ5是上调和CIROF2,CIRC-WWC3,CIRC-DNAJC5,CIRC-KLH12,Circ-IQGAP1和CIRC与对照相比,验证了-A1137655以毫米的下调。 Circ-PTK2和Circ-RNF217与差的治疗响应和存活率相关,而CIRC-AFF2预测MM患者的良好治疗响应和存活率。结论性研究为CIRCRNA表达模式提供了有价值的参考,并验证了CIRC- PTK2,CIRC-RNF217和循环反馈可能是MM中的潜在预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号